Europe
Biopharma companies strengthen their leadership and boards with these appointments.
The TULIP 2 trial was the second Phase III trial that assessed the safety and efficacy of anifrolumab as a treatment for adults with moderate-to-severe SLE.
The funds will be used to support an international research and education collaboration to create new bioindustrial processes using biotechnology and educational programs for students and staff in the industry. They are designed to optimize bioindustrial production and advance a green transformation.
Company’s insulin-based Imotope™ IMCY-0098 shows excellent safety profile and promising clinical trends while eliciting immune responses supporting the proposed mode of action
Promore Pharma AB today announced that the company was granted a patent in Japan for the usage of LL-37 for treating chronic wounds.
Combining the strengths of MAIN5 and Iperion Life Sciences Consultancy for the benefit of the European Pharmaceutical Industry.
This study aimed to determine the appropriate dose for Japanese patients treated with lurbinectedin, in monotherapy, for advanced solid tumors.
Latest development at PCI Dublin site positions it at forefront of EU operations, supporting European expansion and robust Brexit plan for continuity of pharmaceutical supply
Companies from across the globe provide updates on their business and pipelines.
The two companies struck a strategic collaboration and option agreement to harness the power of Immatics’ T-Cell Receptor Engineered T-cell Therapy programs and aim them at solid tumors.
PRESS RELEASES